AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 149 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.35 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,983,000 | -45.1% | 33,155 | -74.2% | 0.00% | -66.7% |
| Q3 2019 | $3,610,000 | -15.1% | 128,593 | +14.4% | 0.00% | +50.0% |
| Q2 2019 | $4,251,000 | +457.1% | 112,372 | +472.5% | 0.00% | – |
| Q1 2019 | $763,000 | -75.4% | 19,628 | -86.5% | 0.00% | -100.0% |
| Q4 2018 | $3,097,000 | -58.3% | 145,324 | -22.6% | 0.00% | 0.0% |
| Q3 2018 | $7,435,000 | +40.8% | 187,816 | +35.9% | 0.00% | 0.0% |
| Q2 2018 | $5,281,000 | +63.4% | 138,249 | +28.5% | 0.00% | 0.0% |
| Q1 2018 | $3,231,000 | +104.2% | 107,599 | +112.4% | 0.00% | +100.0% |
| Q4 2017 | $1,582,000 | +267.1% | 50,650 | +227.9% | 0.00% | – |
| Q3 2017 | $431,000 | +12.8% | 15,449 | -23.0% | 0.00% | – |
| Q2 2017 | $382,000 | +1428.0% | 20,057 | +1170.2% | 0.00% | – |
| Q1 2017 | $25,000 | -64.8% | 1,579 | -60.6% | 0.00% | – |
| Q4 2016 | $71,000 | +317.6% | 4,007 | +316.5% | 0.00% | – |
| Q3 2016 | $17,000 | – | 962 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $36,198,681,000 | 11.58% |
| Sofinnova Investments, Inc. | 1,380,303 | $41,478,000 | 7.13% |
| Casdin Capital, LLC | 450,000 | $13,523,000 | 2.38% |
| Foresite Capital Management III, LLC | 315,331 | $9,476,000 | 2.06% |
| Opaleye Management Inc. | 190,000 | $5,709,000 | 1.63% |
| Redmile Group, LLC | 1,308,526 | $39,321,000 | 1.52% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,384,470 | $41,603,000 | 1.44% |
| Orbimed Advisors | 3,522,100 | $105,839,000 | 1.31% |
| Rock Springs Capital Management LP | 565,000 | $16,978,000 | 0.72% |
| Cormorant Asset Management, LP | 322,945 | $9,704,000 | 0.72% |